Antiviral humoral immunity against SARS-CoV-2 omicron subvariants induced by XBB.1.5 monovalent vaccine in infection-naive and XBB-infected individuals - 22/02/24

Yusuke Kosugi ^{a, b}, Yu Kaku ^a, Alfredo A Hinay ^a, Ziyi Guo ^a, Keiya Uriu ^{a, b}, Minoru Kihara ^c, Fumitake Saito ^d, Yoshifumi Uwamino ^e, Jin Kuramochi ^{f, g}, Kotaro Shirakawa ^h, Akifumi Takaori-Kondo ^h,

The Genotype to Phenotype Japan (G2P-Japan) Consortium

Kei Sato ^{a, b, i, j, k, l, m}

^a Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan 

^b Graduate School of Medicine, The University of Tokyo, Tokyo, Japan 

^c Wakaba Clinic, Kanagawa, Japan 

^d Namikibashi Clinic, Tokyo, Japan 

^e Department of Laboratory Medicine, Keio University School of Medicine, Tokyo, Japan 

^f Interpark Kuramochi Clinic, Utsunomiya, Japan 

^g Department of Global Health Promotion, Tokyo Medical and Dental University, Tokyo, Japan 

^h Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan 

ⁱ International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan 

^j International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan 

^k Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa, Japan 

^l Collaboration Unit for Infection, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, Japan 

^m CREST, Japan Science and Technology Agency, Kawaguchi, Japan 

Le texte complet de cet article est disponible en PDF.